About BridgeBio
BridgeBio is a company based in Palo Alto (United States) founded in 2015 by Neil Kumar and Frank McCormick was acquired by Bristol-Myers Squibb in May 2022.. BridgeBio has raised $434.2 million across 5 funding rounds from investors including KKR, AIG and Hercules Capital. The company has 730 employees as of December 31, 2024. BridgeBio has completed 1 acquisition, including Eidos Therapeutics. BridgeBio offers products and services including Attruby and Nulibry. BridgeBio operates in a competitive market with competitors including Insitro, Moderna, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter Palo Alto, United States
- Employees 730 as on 31 Dec, 2024
- Founders Neil Kumar, Frank McCormick
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Bridgebio Pharma, Inc.
-
Annual Revenue
$221.9 M2285.27as on Dec 31, 2024
-
Net Profit
$-535.76 M16.7as on Dec 31, 2024
-
EBITDA
$-571.29 M3.65as on Dec 31, 2024
-
Total Equity Funding
$434.2 M (USD)
in 5 rounds
-
Latest Funding Round
$200 M (USD), Post-IPO
Apr 30, 2024
-
Investors
KKR
& 19 more
-
Employee Count
730
as on Dec 31, 2024
- Investments & Acquisitions
-
Acquired by
Bristol-Myers Squibb
(May 12, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of BridgeBio
BridgeBio is a publicly listed company on the NASDAQ with ticker symbol BBIO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of BridgeBio
BridgeBio offers a comprehensive portfolio of products and services, including Attruby and Nulibry. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for specific genetic diseases through targeted therapy.
Medicine for genetic conditions affecting patient health.
Unlock access to complete
Leadership Team
82 people
Software Development Team
28 people
Operations Team
23 people
Sales and Marketing
15 people
Human Resources and Administration
12 people
Finance and Accounting
10 people
Senior Team
8 people
Legal and Compliance
7 people
Unlock access to complete
Funding Insights of BridgeBio
BridgeBio has successfully raised a total of $434.2M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $200 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $200.0M
-
First Round
First Round
(13 Sep 2017)
- Investors Count 19
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2024 | Amount | Post-IPO - BridgeBio | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - BridgeBio | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - BridgeBio | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in BridgeBio
BridgeBio has secured backing from 20 investors, including institutional and venture fund investors. Prominent investors backing the company include KKR, AIG and Hercules Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are invested in by this private equity firm.
|
Founded Year | Domain | Location | |
|
Private investment firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by BridgeBio
BridgeBio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Eidos Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Small-molecule treatments for transthyretin amyloidosis are developed.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - BridgeBio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Bridgebio Comparisons
Competitors of BridgeBio
BridgeBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, Moderna, ATAI, Forge Biologics and Spark Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Bridgebio
Frequently Asked Questions about BridgeBio
When was BridgeBio founded?
BridgeBio was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Where is BridgeBio located?
BridgeBio is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Who is the current CEO of BridgeBio?
Neil Kumar is the current CEO of BridgeBio. They have also founded this company.
Is BridgeBio a funded company?
BridgeBio is a funded company, having raised a total of $434.2M across 5 funding rounds to date. The company's 1st funding round was a Post-IPO of $650M, raised on Sep 13, 2017.
How many employees does BridgeBio have?
As of Dec 31, 2024, the latest employee count at BridgeBio is 730.
What is the annual revenue of BridgeBio?
Annual revenue of BridgeBio is $221.9M as on Dec 31, 2024.
What does BridgeBio do?
The company was founded in 2015 in Palo Alto, United States, and operates in the biotechnology sector focused on genetic diseases. Opportunities for therapeutic intervention are identified by mapping genetic disease landscapes. Drug candidates, such as PTCH1-inhibitors for Gorlin syndrome and S1P-lyase inhibitors for Darier and Hailey-Hailey diseases, are advanced through clinical development. Operations emphasize precision medicine approaches to address unmet needs in rare genetic conditions.
Who are the top competitors of BridgeBio?
BridgeBio's top competitors include Moderna, Spark Therapeutics and Forge Biologics.
What products or services does BridgeBio offer?
BridgeBio offers Attruby and Nulibry.
Is BridgeBio publicly traded?
Yes, BridgeBio is publicly traded on NASDAQ under the ticker symbol BBIO.
How many acquisitions has BridgeBio made?
BridgeBio has made 1 acquisition, including Eidos Therapeutics.
Who are BridgeBio's investors?
BridgeBio has 20 investors. Key investors include KKR, AIG, Hercules Capital, Citadel, and Bristol-Myers Squibb.
What is BridgeBio's ticker symbol?
The ticker symbol of BridgeBio is BBIO on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.